年度痛风发作频率作为持续心血管风险的标志:风险分层的临床阈值
结果显示年发作频率与MACE风险呈分级剂量反应关系,高发作频率组7年MACE风险RR 1.45(95%CI 1.37-1.53),中等频率组RR 1.24(1.15-1.33);心衰风险在中、高组均升高,而卒中与心梗风险仅在高组升高。
要点
- 年痛风发作频率是持续心血管风险的分级标志,高频发作(≥7次/年)7年MACE风险RR 1.45。
- 心衰风险在中、高发作频率组均升高,卒中与心梗风险仅在高发作频率组升高。
- 严格发作定义敏感性分析结果一致,支持该频率阈值用于风险分层。
核心结论
- 年痛风发作频率是持续心血管风险的分级标志,高频发作提示更高的MACE风险。
- 心衰风险在中、高发作频率组均升高,而动脉粥样硬化血栓事件主要在高发作频率组出现,提示需要更大的累积炎症暴露。
研究设计与样本
- 使用TriNetX全球协作网络,识别2017年首次电子病历记录并接受治疗的痛风发作成人患者。
- 采用12个月landmark暴露窗口,按年发作频率分为低(≤3)、中(4-6)、高(≥7)三组,随访改良MACE(心梗、卒中、心衰)。
- 组间比较采用1:1倾向评分匹配,并进行 stricter 发作定义(痛风诊断且0-3天内使用秋水仙碱、糖皮质激素或关节腔注射,排除NSAIDs)的敏感性分析。
主要发现
- 7年时MACE风险在高发作频率组RR 1.45(95%CI 1.37-1.53),中等频率组RR 1.24(1.15-1.33),呈分级剂量反应。
- 心衰风险在高组HR 1.27、中组HR 1.17均升高;卒中和心梗仅在高组升高(7年HR均1.28),卒中从3年起显著。
- stricter 敏感性定义下结果一致:7年MACE高组HR 1.19、中组HR 1.12。
关键数值与推荐
- 年发作频率分组阈值:低≤3次/年,中4-6次/年,高≥7次/年。
- 7年MACE风险:高组RR 1.45(95%CI 1.37-1.53),中组RR 1.24(95%CI 1.15-1.33),对比低组。
- 心衰风险:高组HR 1.27,中组HR 1.17;卒中和心梗仅高组7年HR 1.28(卒中从3年显著)。
- 敏感性分析7年MACE:高组HR 1.19,中组HR 1.12。
临床怎么用
- 可将年痛风发作频率作为痛风患者心血管风险分层的简易临床指标,高频发作(≥7次/年)提示需强化心血管风险评估与管理。
- 中等发作频率(4-6次/年)患者应关注心衰风险,高频发作患者还需警惕卒中和心梗风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We examined whether annual gout flare frequency, as a marker of cumulative inflammatory burden, predicts long-term major adverse cardiovascular events (MACEs). METHODS: Using the TriNetX Global Collaborative Network, we identified adults with a first EHR-recorded treated gout flare in 2017. Using a 12-month landmark exposure window, patients were classified as low (≤3), moderate (4-6) or high (≥7) flares/year. Modified MACE (myocardial infarction, stroke, heart failure) was followed from the landmark. Groups were compared using 1:1 propensity score matching. A sensitivity analysis applied a stricter flare definition (gout diagnosis with colchicine, corticosteroid or intra-articular injection within 0-3 days; NSAIDs excluded). RESULTS: Among 44 705 patients, matching produced balanced cohorts (high vs low, 13 179 pairs; moderate vs low, 9700 pairs). A graded dose-response was observed: at 7 years, MACE risk was higher in the high (RR 1.45; 95% CI 1.37-1.53) and moderate (RR 1.24; 1.15-1.33) groups vs low. Heart failure risk was elevated in both the groups (HR 1.27 [high]; 1.17 [moderate]); stroke and myocardial infarction were elevated only in the high group (7-year HR 1.28 each), with stroke significant from 3 years. Findings were consistent under the stricter sensitivity definition (7-year MACE HR 1.19 [high] and 1.12 [moderate]). CONCLUSION: Annual gout flare frequency is a graded marker of sustained cardiovascular risk. Heart failure risk rises with both moderate and high burden, whereas atherothrombotic events emerge predominantly with high-flare frequency, suggesting they require greater cumulative inflammatory exposure.
引用
- Tung KT, Chen SC, Lee C, et al. Annual gout flare frequency as a marker of sustained cardiovascular risk: a clinical threshold for risk stratification. Rheumatology (Oxford). 2026. PMID: 42462116. doi:10.1093/rheumatology/keag370
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。